Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.305
+0.055 (1.29%)
Jun 10, 2026, 10:14 AM EDT - Market open

Radiopharm Theranostics Revenue

Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.

Revenue (ttm)
16.28M AUD
Revenue Growth
+4,823.49%
P/S Ratio
4.37
Revenue / Employee
1,162,745 AUD
Employees
14
Market Cap
47.40M USD

Revenue Chart

* This company reports financials in AUD.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202512.51M10.55M538.86%
Jun 30, 20241.96M-4.25M-68.46%
Jun 30, 20236.21M--
Jun 30, 2022---
Jun 30, 2021---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Xilio Therapeutics53.48M
Metagenomi Therapeutics22.33M
Veru Inc.16.89M
Immutep5.28M
Mereo BioPharma Group500.00K
aTyr Pharma190.00K
Revenue Rankings